AIM: To determine the degree of variation in the handling of prostate needle biopsies (PBNx) in laboratories across Europe. METHODS: A web based survey was emailed to members of the European Network of Uropathology and the British Association of Urological Pathologists. RESULTS: Responses were received from 241 laboratories in 15 countries. PNBx were generally taken by urologists (93.8%) or radiologists (23.7%) but in 8.7% were also taken by non-medical personnel such as radiographers, nurses or biomedical assistants. Of the responding laboratories, 40.8% received cores in separate containers, 42.3% processed one core/block, 54.2% examined three levels/block, 49.4% examined one H&E section/level and 56.1% retained spare sections for potential immunohistochemistry. Of the laboratories, 40.9% retained unstained spares for over a year while 36.2% discarded spares within 1 month of reporting. Only two (0.8%) respondents routinely performed immunohistochemistry on all PNBx. There were differences in laboratory practice between the UK and the rest of Europe (RE). Procurement of PNBx by non-medical personnel was more common in the UK. RE laboratories more commonly received each core in a separate container, processed one core/block, examined fewer levels/block and examined more H&E sections/level. RE laboratories also retained spares for potential immunohistochemistry less often and for shorter periods. Use of p63 as the sole basal cell marker was more common in RE. CONCLUSIONS: There are marked differences in procurement, handling and processing of PNBx in laboratories across Europe. This data can help the development of best practice guidelines.
AIM: To determine the degree of variation in the handling of prostate needle biopsies (PBNx) in laboratories across Europe. METHODS: A web based survey was emailed to members of the European Network of Uropathology and the British Association of Urological Pathologists. RESULTS: Responses were received from 241 laboratories in 15 countries. PNBx were generally taken by urologists (93.8%) or radiologists (23.7%) but in 8.7% were also taken by non-medical personnel such as radiographers, nurses or biomedical assistants. Of the responding laboratories, 40.8% received cores in separate containers, 42.3% processed one core/block, 54.2% examined three levels/block, 49.4% examined one H&E section/level and 56.1% retained spare sections for potential immunohistochemistry. Of the laboratories, 40.9% retained unstained spares for over a year while 36.2% discarded spares within 1 month of reporting. Only two (0.8%) respondents routinely performed immunohistochemistry on all PNBx. There were differences in laboratory practice between the UK and the rest of Europe (RE). Procurement of PNBx by non-medical personnel was more common in the UK. RE laboratories more commonly received each core in a separate container, processed one core/block, examined fewer levels/block and examined more H&E sections/level. RE laboratories also retained spares for potential immunohistochemistry less often and for shorter periods. Use of p63 as the sole basal cell marker was more common in RE. CONCLUSIONS: There are marked differences in procurement, handling and processing of PNBx in laboratories across Europe. This data can help the development of best practice guidelines.
Authors: T Van der Kwast; L Bubendorf; C Mazerolles; M R Raspollini; G J Van Leenders; C-G Pihl; P Kujala Journal: Virchows Arch Date: 2013-08-06 Impact factor: 4.064
Authors: Teemu T Tolonen; Jorma Isola; Antti Kaipia; Jarno Riikonen; Laura Koivusalo; Sanna Huovinen; Marita Laurila; Sinikka Porre; Mika Tirkkonen; Paula Kujala Journal: BMC Clin Pathol Date: 2015-03-08
Authors: Andrea Chatrian; Richard T Colling; Jens Rittscher; Clare Verrill; Lisa Browning; Nasullah Khalid Alham; Korsuk Sirinukunwattana; Stefano Malacrino; Maryam Haghighat; Alan Aberdeen; Amelia Monks; Benjamin Moxley-Wyles; Emad Rakha; David R J Snead Journal: Mod Pathol Date: 2021-05-20 Impact factor: 7.842